Literature DB >> 22198598

AICAR, a small chemical molecule, primes osteogenic differentiation of adult mesenchymal stem cells.

Wei Wu1, Zhaoyang Ye, Yan Zhou, Wen-Song Tan.   

Abstract

The chemical approach to controlling stem cell fates is emerging as a powerful tool, holding great promise in tissue engineering and regenerative medicine. Various small molecules have been demonstrated capable of modulating stem cell differentiation. In this paper, we studied the effects of 5-aminoimidazole-4-carboxamide-1-ß-riboside (AICAR), an activator of AMP-activated protein kinase (AMPK), on mesenchymal stem cells (MSCs). AICAR at high concentrations (1.0-2.0 mM) significantly inhibited proliferation of both human amnion-derived MSCs (hAMSCs) and rabbit bone marrow-derived MSCs (BM-MSCs). Most importantly, AICAR efficiently promoted the osteogenic differentiation of hAMSCs and BM-MSCs in both growth medium and osteogenic medium. However, Metformin, another AMPK activator, showed no such effects. Meanwhile, AICAR significantly inhibited adipogenic differentiation of hAMSCs and BM-MSCs. Our data suggests that AICAR represents a potent molecule, which can be applied in bone tissue regeneration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198598     DOI: 10.5301/ijao.5000007

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  14 in total

1.  Engineering cells with intracellular agent-loaded microparticles to control cell phenotype.

Authors:  James A Ankrum; Oscar R Miranda; Kelvin S Ng; Debanjan Sarkar; Chenjie Xu; Jeffrey M Karp
Journal:  Nat Protoc       Date:  2014-01-09       Impact factor: 13.491

Review 2.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

3.  Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women.

Authors:  Sahar Kamal Hegazy
Journal:  J Bone Miner Metab       Date:  2014-03-15       Impact factor: 2.626

Review 4.  The role of small molecules in musculoskeletal regeneration.

Authors:  Kevin W-H Lo; Keshia M Ashe; Ho Man Kan; Cato T Laurencin
Journal:  Regen Med       Date:  2012-07       Impact factor: 3.806

5.  Human amnion mesenchymal stem cells promote proliferation and osteogenic differentiation in human bone marrow mesenchymal stem cells.

Authors:  Yuli Wang; Ying Yin; Fei Jiang; Ning Chen
Journal:  J Mol Histol       Date:  2014-11-29       Impact factor: 2.611

6.  Simulated Body Fluid Nucleation of Three-Dimensional Printed Elastomeric Scaffolds for Enhanced Osteogenesis.

Authors:  Nathan J Castro; Wilhelmina Nanrui Tan; Charlie Shen; Lijie Grace Zhang
Journal:  Tissue Eng Part A       Date:  2016-07-07       Impact factor: 3.845

7.  Mice lacking AMP-activated protein kinase α1 catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment.

Authors:  J Jeyabalan; M Shah; B Viollet; J P Roux; P Chavassieux; M Korbonits; C Chenu
Journal:  J Endocrinol       Date:  2012-06-14       Impact factor: 4.286

Review 8.  Current View on Osteogenic Differentiation Potential of Mesenchymal Stromal Cells Derived from Placental Tissues.

Authors:  Gabriela Kmiecik; Valentina Spoldi; Antonietta Silini; Ornella Parolini
Journal:  Stem Cell Rev Rep       Date:  2015-08       Impact factor: 5.739

Review 9.  Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review.

Authors:  A Palermo; L D'Onofrio; R Eastell; A V Schwartz; P Pozzilli; N Napoli
Journal:  Osteoporos Int       Date:  2015-04-25       Impact factor: 4.507

10.  The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing.

Authors:  J Jeyabalan; B Viollet; P Smitham; S A Ellis; G Zaman; C Bardin; A Goodship; J P Roux; M Pierre; C Chenu
Journal:  Osteoporos Int       Date:  2013-05-04       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.